Avex Healthcare Empower LLC (Headquarters: Minato-ku, Tokyo, Representative: Yasuto Yasuyama, hereinafter referred to as AHE) is a subsidiary of HIROTSU Bioscience Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, Representative Director: Takasuke Hirotsu, We are cooperating to promote the nematode cancer test N-NOSE®, a technology developed by HBS.
To commemorate the significant expansion of the cancer types that can be treated by the nematode cancer test “N-NOSE” developed and provided by HBS from 15 to 23, the event was held at Kanda Myojin Shrine on Tuesday, December 3rd. The “N-NOSE Cancer Type Expansion Event” was held at .
Table tennis player Miwa Harimoto will appear as a guest at this event. Harimoto, who won medals in various competitions this year and achieved remarkable success, was elevated to the Kanda Myojin Shrine and received prayers for “thanks to God” and “fulfilment of his heart’s wishes.” Afterwards, he looked back on the past year and talked about his feelings for many people, including his parents and fans, and his gratitude for being able to spend the year without any major injuries or illnesses, as well as his and his parents’ health and plans for further progress. .
Additionally, to commemorate the fact that the number of cancer types that respond to N-NOSE has expanded significantly, it has been decided that Harimoto’s parents will be presented with N-NOSE on a regular basis. Harimoto said, “I’m especially grateful for the support of my parents, and I hope they stay healthy forever.” Harimoto concluded the event by expressing his expectations for the powered-up N-NOSE.
■Miwa Harimoto comment
Although it was a year that included a big event called the Olympics, I think I was able to maintain a good performance without any major injuries or illnesses. We were encouraged by the support of many people, including our fans. I am especially grateful to my parents who have supported me over the past year.
This time, we received a wonderful story about being able to provide “N-NOSE” to parents on a regular basis. I hope that my parents will stay healthy forever after being tested with the powered-up “N-NOSE”!
■Comment from Takasuke Hirotsu, Representative Director of HIROTSU Bioscience Co., Ltd.
To commemorate the expansion of the target cancer types for the primary cancer screening test “N-NOSE” from 15 to 23 types through clinical research, we will be offering “N-NOSE” to parents through table tennis player Miwa Harimoto. We are very happy to be able to offer this to you.
At the age of 15, Miwa Harimoto decided to participate in the tournament, which was her dream, and achieved amazing results by winning a silver medal at the age of 16. I was very moved to hear that his success was due to the good health and devoted support of his parents. I hope that Harimoto will continue to focus on his studies and table tennis, and move toward his dreams with peace of mind.
I would like to inform everyone that the cancer has spread, and I would like to support Mr. Harimoto so that his dreams can also expand.
■“N-NOSE® evolve” (Yomi: Nnose Evolve)
●Do not freeze and can be carried within 4 hours to 8 hours
Improvements in specimen storage technology have made it unnecessary to use ice packs, which were previously required for specimen submission. Additionally, the time required to submit a specimen within 4 hours has been extended to 8 hours, and the size of the test kit has been reduced to approximately 1/2.
●The number of cancer types that respond to this drug has expanded from 15 to 23.
Thanks to the results of continuous clinical research, the scope of cancer detection has expanded significantly (99% coverage rate).*1).
Oral cancer (including tongue and gum cancer), pharyngeal cancer, laryngeal cancer (including glottic cancer), thyroid cancer, esophageal cancer, lung cancer, breast cancer, stomach cancer, gastrointestinal stromal tumor ( GIST), liver cancer, gallbladder cancer, Bile duct cancer, pancreatic cancer, kidney cancer, colorectal cancer, cervical cancer, uterine cancer, ovarian cancer, testicular cancer, prostate cancer, bladder cancer, skin cancer, blood cancer ( (including malignant lymphoma, multiple myeloma, leukemia)
The above advancements have greatly improved convenience for users, and with the expansion of cancer types, the coverage rate for examining cancer risk throughout the body with a single test has improved, making it more functional as a primary screening test. has increased.
Early detection of cancer not only reduces the physical and mental burden on users, but also reduces the number of deaths from cancer and significantly reduces medical costs, which provides social benefits. We will continue to use this unique technology to create a world where cancer can be detected early and protect people’s health and future security.
*1(Note) Figures are based on the “National Cancer Registry Incidence Number and Rate Report 2019,” which is limited to cancer types counted by the Ministry of Health, Labor and Welfare. N-NOSE coverage rate for all cancer patients.
■About “N-NOSE”
A test to determine cancer risk that utilizes the ability of the nematode C. elegans, which has an excellent sense of smell, to highly accurately detect cancer-specific odors in human urine. By simply submitting urine, it is possible to investigate the risk of cancer at an early stage in a simple, inexpensive, highly accurate, and comprehensive manner. 700,000 since launch in 2020*2 We have a sales record of
Service site:https://lp.n-nose.com/
*2 Sales results as of September 24, 2024
■About “N-NOSE plus”
N-NOSE’s next-generation “cancer type identification test”. We use a “special nematode” created by genetically engineering the nematode C. elegans that responds specifically to the smell of a specific cancer type. This “special nematode” has a high ability to distinguish between specific cancer types and other cancers, making it possible to determine the risk of each cancer type using a non-invasive method. . We are currently treating pancreatic cancer and liver cancer.
Service site:https://lp.n-nose.com/
■About “N-NOSE Animal”
“N-NOSE Dog”, a cancer test for dogs, and “N-NOSE Neko-chan”, a cancer test for cats developed using N-NOSE’s technology. Until now, there has not been a cancer test that can be easily taken by dogs and cats that do not show any symptoms, but this test can check the risk of multiple cancers by simply submitting urine, just like in humans. You can. We started providing the service in 2023.
Service site:https://lp.n-nose.com/animal/
![[Daily Hirai]The 8th EP in the “LUCKY BAG” series “Christmas Wish” will be released on Wednesday, December 11th!](https://tokytunes.com/wp-content/uploads/2024/12/Daily-HiraiThe-8th-EP-in-the-LUCKY-BAG-series-Christmas-768x768.jpg)
